Trevena Reports First Quarter 2021 Results
May 06, 2021 07:00 ET | Source: Trevena Inc. Trevena Inc.
Company reaffirms YE target of 100 formulary approvals for OLINVYK®
Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and cognitive function
TRV027 selected for two large, multi-site COVID-19 studies led by NIH / Vanderbilt University Medical Center and REMAP-CAP
TRV045 IND filing remains on track for 1H 2021 with a lead target indication of diabetic neuropathic pain
$97.7M cash at Q1 funds operations through YE 2022
th
CHESTERBROOK, Pa., May 06, 2021 (GLOBE NEWSWIRE)
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the first quarter ended March 31, 2021, and provided an overview of its recent operational
Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Trevena Reports First Quarter 2021 Results
mychesco.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mychesco.com Daily Mail and Mail on Sunday newspapers.
Trevena Reports First Quarter 2021 Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Trevena to Release Fourth Quarter and Full Year 2020 Financial Results
mychesco.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mychesco.com Daily Mail and Mail on Sunday newspapers.